Failure of therapy or resistance to antiplatelet drugs?

Antiplatelet therapy: to tailor or not to tailor?

We have all been witnessing the steep upward trend in mobile device usage and their increasing sophistication which will no doubt continue. We used to use our mobile phones to make calls and possibly to send a text message, but now we check our emails, reserve cinema tickets, and, of course, read the latest journal articles via our smartphones and tablets. At Oxford University Press, we launche...

Antiplatelet drugs.

Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is recommended as the first-line antiplatelet drug. Cl...

Platelet function tests and resistance to antiplatelet therapy.

The clinical efficacy of antiplatelet therapy (aspirin, P2Y12 and glycoprotein IIb/IIIa receptor antagonists) to prevent occlusive arterial events in patients with atherothrombotic disease is well established. Despite the proven benefits of antiplatelet therapy, many patients continue to experience arterial events. Many factors may influence the response of platelets to antiplatelet therapy and...

Impaired Hemorheological Parameters and Resistance to Routine Antiplatelet Therapy

Therapeutic failure or resistance to aspirin.

1. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20. 2. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE st...